secwatch.observer — SEC 8-K summary
======================================

Issuer:     MIMEDX GROUP, INC. (MDXG)
CIK:        0001376339
Form:       8-K
Filed at:   2025-02-26T23:59:59+00:00
Accession:  0001376339-25-000011
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MiMedx Q4 net sales $93M (+7% YoY), Adjusted EBITDA margin 21%, guides high-single-digit growth for 2025
--------------------------------------------------------------------------------

- Q4 2024 net sales $93M (+7% YoY); full year $349M (+9% YoY). Adjusted EBITDA margin 21% for Q4.
- GAAP net income Q4 $7M ($0.05 EPS); full year $42M. Cash $104M at Dec 31, net cash $86M.
- 2025 outlook: net sales growth at least high single-digits, Adjusted EBITDA margin above 20%.
- SG&A increased to $61M in Q4 from $54M a year ago; CEO cites Medicare disruption but remains confident.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1376339/000137633925000011/0001376339-25-000011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1376339/000137633925000011/mdxg-20250226.htm
  HTML page:      https://secwatch.observer/filing/0001376339-25-000011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer